Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.

Check also Companies to Follow in 2022 and CMN Markets for the latest stock and market trends.

Always stay updated with the free CMN Newsletter.


Main focus: Stem cell engineering for treatment of diabetes

Company stage: Clinical

Diseases: Type 1 and 2 diabetes

Genome editing tool: CRISPR-Cas9

Funding stage: Private

Location: San Diego, CA, USA



Partners: CRISPR Therapeutics

Viacyte is developing engineered stem cells in order to treat diabetes. The company has an ongoing collaboration with CRISPR Therapeutics, for which the companies seek to develop a next generation stem cell product for all type 1 diabetes and insulin-requiring type 2 diabetes patients. The programme is currently in a research phase.


HashtagViaCyte, Inc.

Company: Viacyte
Jobs, banner ads, webinars, sponsored content...
Search CRISPR Medicine